According to new preliminary research, women who experience early menopause are more likely to develop dementia later in life. For women nearing the menopause transition, this has raised the question of whether or not early menopause can cause dementia.
In this article, we will discuss the relationship between early menopause and dementia risk, the role of estrogen, and what this means for women who enter menopause early.
According to preliminary research from a large UK cohort study published in April of 2022, early menopause is linked to an increased risk of presenile (early-onset) dementia before age 65. The study used cohort data from UK Biobank to include a total of 153,291 postmenopausal women. Age at menopause was categorized as:
*Note: The average age of menopause onset for women in the U.S. is 51.
The primary outcome was all-cause dementia, which included Alzheimer’s disease, vascular dementia, and dementia classified elsewhere. After adjusting for factors such as age at last follow-up, race, education level, body mass index (BMI), cigarette smoking, alcohol consumption, cardiovascular disease status, and diabetes status, the analysis found that:
The researchers concluded that women with early menopause should be closely monitored for cognitive decline in clinical practice. This large study supported previous findings from other studies assessing the association between reproductive period and risk of dementia, such as this diverse cohort study of health care members. This study which analyzed 15,754 women found that:
While some previous studies demonstrated mixed findings, these large, diverse studies suggest a strong relationship between early menopause and dementia risk.
During the menopause transition, production of the female sex hormone, estrogen, drops significantly. While most women typically enter menopause in their early 50s, many women enter menopause earlier, whether naturally, due to hysterectomy, or due to a medical condition.
Researchers currently believe that lower estrogen levels may be a factor involved in the increased dementia risk associated with early menopause. While the exact mechanism linking the two is not yet known, several mechanisms have been proposed:
Many women are curious if hormone therapy can help combat the increased dementia risk for those who enter menopause early. Several observational studies have reported a protective effect of hormone therapy on dementia risk. However, more recently, a Women’s Health Initiative study showed that taking estrogen and progestin after menopause may increase women’s risk for heart disease, stroke, blood clots, urinary incontinence, and breast cancer.
Research linking early menopause to increased dementia risk has understandably left many women uneasy. It is important to understand that early menopause does not necessarily cause dementia—not all women who enter menopause early will go on to develop dementia later in life. There are also several well-established Alzheimer’s and dementia prevention strategies that women who enter early menopause can implement that may reduce their risk. Many of these prevention techniques include quitting smoking, controlling alcohol consumption, eating a heart-healthy diet, exercising daily, getting sufficient sleep, minimizing stress, and engaging mentally and socially.
For women who enter menopause early or for anyone at a higher risk of developing dementia, it is crucial to monitor brain health early and frequently. Like many other diseases and disorders, early intervention and early treatment of Alzheimer’s and other causes of dementia is believed to offer the best chance of therapeutic success and produce better health outcomes.
At Altoida, we are dedicated to providing a reliable, affordable, and highly accurate way to measure and monitor your brain health. We are building the world’s-first Precision Neurology platform and app-based medical device—backed by 11 years of clinical validation—to accelerate and improve drug development, neurological disease research, and patient care.
By completing a 10-minute series of augmented reality and motor activities designed to simulate complex Activities of Daily Living on a smartphone or tablet, Altoida’s device extracts and provides robust measurements of neurocognitive function across 13 neurocognitive domains. Our device measures and analyzes nearly 800 multimodal cognitive and functional digital biomarkers. Through the collection of highly granular data from integrated smartphone or tablet sensors, Altoida’s device produces comprehensive neurocognitive domain scores. This data can be tracked longitudinally to reveal trends and patterns while flagging concerning ones.
This method, along with our innovative artificial intelligence, will pioneer fully digital predictive neurological disease diagnosis. Recently receiving Breakthrough Device designation by the FDA, Altoida's platform has demonstrated ability to predict conversion from Mild Cognitive Impairment to Alzheimer's disease with a high degree of accuracy.
To learn more about if there is a test for Parkinson’s disease or about utilizing Altoida’s Precision Neurology platform, contact us today.